A series of new highly potent LH‐RH antagonists (T‐series) has been synthesized in our laboratory. Among these analogs, antagonists [Ac‐d‐Nal(2), d‐Phe(4Cl)2. d‐Pal(3)3, d‐Lys(A2pr(Car)2)6, d‐Ala10LH‐RH (T‐140); [Ac‐d‐Nal(2)1, d‐Phe(4Cl)2, d‐Pal(3)3, d‐Lys(A2pr(Ac)2)6, d‐Ala10]LH‐RH (T‐148); [Ac‐d‐Nal(2)1, d‐Phe(4Cl)2, d‐Pal(3)3, d‐Lys(A2pr(For)2)6, d‐Ala10)]LH‐RH (T‐151) and [Ac‐d‐Nal(2)1, d‐Phe(4cl)2, d‐Pal(3)3, d‐Lys(A2bu(For)2)6, d‐Ala10]LH‐RH (T‐159) were the most powerful. Antagonists T‐140, T‐148 and T‐151 produced a complete blockade of ovulation in normal cycling rats at a dose of 1.5 μg/rat and antagonist T‐159 at a dose of only 0.75 μg/rat. The inhibitory effects of compounds T‐148, T‐151 and T‐159 on gonadotropin and sex steroid secretion were investigated in male and female rats. To determine their effect on LH levels in castrated male and ovariectomized female rats, T‐148, T‐151 and T‐159 were injected subcutaneously in doses of 0.625 and 2.5 μg/rat. Blood samples were taken at different intervals for 48 h. All three compounds at either dose caused a significant (P< 0.01) decrease in LH levels for more than 6 h. Significant (P <0.01) inhibition of LH lasted for more than 24 h following a dose of 2.5 μg sc of all 3 antagonists in both male and female rats. Serum FSH levels were also suppressed significantly for more than 48 h in castrated male rats by all three antagonists at a dose of 5 μg/rat sc. Serum testosterone levels were measured in intact male rates injected with antagonists T‐148, T‐151 and T‐159 in doses of 50 and 100 pg sc. Both doses produced a dramatic fall in testosterone (P<0.01) to castration levels 6 h after injection. The inhibition of serum testosterone lasted for more than 48 h, but only 100 μg of T‐148 maintained testosterone in the castration range for more than 48 h. Antagonists T‐148, T‐151 and T‐159 injected at a dose of 100 μg to intact female rats reduced serum estradiol levels significantly (P<0.01) for more than 48 h, as compared to control animals. In the cutaneous anaphylactoid test (CAT), T‐148, T‐151 and T‐159 proved to have very low histamine releasing activities. These data demonstrate a high efficacy of these new LH‐RH antagonists in suppressing the pituitary‐gonadal axis in male and female rats. These LH‐RH antagonists could possibly be used for treatment of sex‐hormone sensitive cancers and other disorders and conditions, in which a reduction in circulating sex steroids would be beneficial.